Keywords: integrilin, disappoints, early, acs, study, drug, major

Integrilin disappoints in EARLY ACS study

Article | 09 April 2009

Print This

US drug major Schering-Plough's Integrilin (eptifibatide) failed to achieve either the primary or secondary endpoints of a trial testing the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in